Evidence map›Paper›PMID 41639279›Full record

ArticleActa neuropathologica2026

A HIF1A variant impacts long-term disability and smoldering inflammation in multiple sclerosis.

Antonino Giordano, Pernilla Stridh, Paolo Preziosa, Marco Pisa, Celia Lerma-Martin, Melissa Sorosina, Elisabetta Mascia, Silvia Santoro, Kaalindi Misra, Ferdinando Clarelli and 25 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Antonino GiordanoHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Pernilla StridhDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Paolo PreziosaUnit of Neurology and MS Center, IRCCS San Raffaele Hospital, Milan, Italy.
Marco PisaAcademic Unit of Neuropathology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Celia Lerma-MartinDepartment of Neurology, Division of Neuroimmunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Melissa SorosinaHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Elisabetta MasciaHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Silvia SantoroHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Kaalindi MisraHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Ferdinando ClarelliHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Laura FerrèHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Maria NeedhamsenDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Ali ManouchehriniaDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Matteo MissagliaHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Thomas MoridiDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Klementy ShchetynskyDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Russell OuelletteDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Adil HarroudThe Neuro (Montreal Neurological Institute-Hospital), Montréal, QC, Canada.
Elisabeth de VriesDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Subita Balaram KuttikkatteOxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Fredrik PiehlDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Lars AlfredssonDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Jan HillertDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Tomas OlssonDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Lars FuggerMRC Human Immunology Unit, University of Oxford, Oxford, UK.
Kathrine AttfieldOxford Centre for Neuroinflammation, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Tobias GranbergDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Lucas SchirmerDepartment of Neurology, Division of Neuroimmunology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Martina AbsintaExperimental Neuropathology Lab, IRCCS Humanitas Research Hospital, Milan, Italy.
Maja JagodicDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Gabriele Carmine DeLucaAcademic Unit of Neuropathology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Maria A RoccaUnit of Neurology and MS Center, IRCCS San Raffaele Hospital, Milan, Italy.
Massimo FilippiUnit of Neurology and MS Center, IRCCS San Raffaele Hospital, Milan, Italy.
Ingrid KockumDepartment of Clinical Neuroscience, Karolinska Institutet, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
Federica EspositoHuman Genetics of Neurological Disorders, Division of Neuroscience, San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy. esposito.federica@hsr.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) shows a highly heterogeneous course, with some patients accumulating severe disability early while others remain relatively preserved even after decades. A key driver of disability progression is smoldering inflammation, a chronic, compartmentalized immune process at the edge of chronic active lesions. However, the factors driving smoldering inflammation in MS remain incompletely understood. We investigated the role of genetic variation in smoldering inflammation-related genes across two independent MS cohorts, using a discovery-replication design in a total of 2,817 patients. We identified a locus in the HIF1A (Hypoxia-Inducible Factor 1-alpha) gene that is associated with a more favorable disease course at over 20 years from disease onset. Using additional independent cohorts, we found that carriers of the HIF1A protective allele exhibited lower paramagnetic rim lesion volume on MRI, lower plasma and cerebrospinal fluid neurofilament levels, and reduced microglial/macrophage inflammation with less axonal injury in post-mortem progressive MS tissue. By integrating single-nucleus RNA sequencing and spatial transcriptomics, we showed that the HIF1A variant dynamically modulates gene expression in a cell-type specific and context-dependent manner in the MS brain. Collectively, these findings highlight a protective HIF1A variant associated with a more favourable long-term disease course and reduced smoldering inflammation, opening new avenues to translate this genetic discovery into new potential strategies to tackle disease progression.

Indexed as

Hypoxia-Inducible Factor 1, alpha SubunitInflammationMultiple SclerosisAdultBrainCohort StudiesDisease ProgressionFemaleHumansMaleMiddle AgedHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitDisabilityHypoxiaMultiple sclerosisParamagnetic rim lesionsProgressionSmoldering inflammation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.